Company Description
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular the...
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.
Valuation
Price to Sales Ratio
25.91
Price to Book Ratio
18.58
Enterprise Value to EBITDA
-1.68
Enterprise Value to Sales
9.81
Efficiency
Total Asset Turnover
0.08
Liquidity
Current Ratio
1.24
Quick Ratio
1.18
Cash Ratio
0.91
Profitability
Gross Margin
67.54
Operating Margin
-695.68
Pretax Margin
-874.28
Net Margin
-809.63
Return on Assets
-62.45
Return on Equity
-351.23
Return on Total Capital
-117.62
Capital Structure
Total Debt to Total Assets
30.74
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. Henry H. Ji | 57 | 2006 | President, Chief Executive Officer & Director |
Dr. Shawn Sahebi | - | - | Senior Vice President-Strategy & Analytics |
Ms. Elizabeth Adkins Czerepak | 65 | 2021 | Independent Director |
Dr. Robert D. Allen | - | - | Senior Vice President-Research & Development |
Dr. Mike A. Royal | 66 | 2014 | Chief Medical Officer |
Insider Actions
12/21/2022 |
Henry H. Ji See Remarks; Director |
300 | 1,650 | |
12/15/2022 |
Henry H. Ji See Remarks; Director |
1,500,000 | Award at $0 per share. | 0 |
12/02/2022 |
Henry H. Ji See Remarks; Director |
200 | 1,100 | |
09/07/2022 |
Henry H. Ji See Remarks; Director |
88,888 | Acquisition at $2.02 per share. | 179,553 |
09/06/2022 |
Henry H. Ji See Remarks; Director |
55,555 | Acquisition at $1.96 per share. | 108,887 |
09/02/2022 |
Henry H. Ji See Remarks; Director |
2,500,000 | Award at $0 per share. | 0 |
08/26/2022 |
Henry H. Ji See Remarks; Director |
33,333 | Acquisition at $2.11 per share. | 70,332 |
08/25/2022 |
Henry H. Ji See Remarks; Director |
22,222 | Acquisition at $2.06 per share. | 45,777 |
06/14/2022 |
Henry H. Ji See Remarks; Director |
10,000 | Acquisition at $1.4 per share. | 14,000 |
12/27/2021 |
Kim D. Janda Director |
3,000 | Disposition at $5.88 per share. | 17,640 |
12/27/2021 |
Kim D. Janda Director |
3,000 | Derivative/Non-derivative trans. at $4 per share. | 12,000 |
MarketWatch News on SRNE
-
Biotech Stocks Are Up by Double Digits. It's Still a Bear Market.
- Barron's Online
-
Sorrento Therapeutics says initial testing showed its COVISTIX test demonstrated ability to detect omicron variant
- Tomi Kilgore
-
Sorrento Therapeutics started at buy with $26 stock price target at B. Riley
- Tomi Kilgore
-
Charting market rotation, S&P 500 presses record territory
- Michael Ashbaugh
-
Charting market rotation, S&P 500 presses record territory
- Michael Ashbaugh
-
Sorrento stock falls after company fires CFO
- Wallace Witkowski
-
Sorrento Therapeutics started at buy with $24 stock price target at Dawson James Securities
- Tomi Kilgore
-
America’s New Pastime: Day Trading
- Barron's Online
-
Sorrento stock's intraday high of $10 was nearly 4 times Thursday's closing price
- Tomi Kilgore
-
Sorrento Therapeutics' stock gains 1.9%, but pares earlier surge of as much as 48%
- Tomi Kilgore
-
Stocks Rise Because There Is ‘No Limit’ to What Fed Can Do
- Barron's Online
-
Sorrento Therapeutics' stock soars 44% premarket, after rocketing 158% on Friday
- Tomi Kilgore
- Loading more headlines...
Other News on SRNE
-
10-Q: SORRENTO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Sorrento Therapeutics: Down The Rabbit Hole
- Seeking Alpha
-
Sorrento in credit agreement with B. Riley for $41.7M
- Seeking Alpha
-
Why Sorrento Therapeutics Stock Is Marching Higher Today
- Motley Fool
-
2 Penny Stocks That Could Make You Filthy Rich
- Motley Fool
-
Why Sorrento Therapeutics Stock Is Popping Today
- Motley Fool
-
Sorrento Therapeutics: COVISTIX Sales Are Lagging Behind
- Seeking Alpha
- Loading more headlines...